SANOFI-AVENTIS (EPA:SAN) | WebDisclosure

Basculer en Français

10820	Companies
234679	Keywords
163541	Articles
125594	Press releases

Home
Companies
SANOFI-AVENTIS

PRESS RELEASE

published on 06/04/2026 at 10:07, 2 months 7 days ago

Press Release: Sanofi launches 2026 global employee stock purchase plan
Sanofi launches Action 2026 global employee stock purchase plan involving 75,000 employees in 52 countries. Employees offered discounted shares with free matching shares and limited purchase amount. Eligibility conditions and holding periods apply

Shares Sanofi Global Employee Stock Purchase Plan Action 2026
BRIEF

published on 05/28/2026 at 07:05, 2 months 15 days ago

Sanofi's venglustat under priority review by the FDA for type 3 Gaucher disease

FDA Sanofi Venglustat Gaucher's Disease Priority Examination
BRIEF

published on 05/28/2026 at 07:05, 2 months 15 days ago

Sanofi's Venglustat Granted Priority Review for Type 3 Gaucher Disease

Sanofi FDA Review Venglustat Gaucher Disease Neurological Treatment
BRIEF

published on 05/28/2026 at 07:05, 2 months 15 days ago

Le venglustat de Sanofi obtient un examen prioritaire pour la maladie de Gaucher de type 3

Sanofi Examen De La FDA Venglustat Maladie De Gaucher Traitement Neurologique
BRIEF

published on 05/28/2026 at 07:05, 2 months 15 days ago

Le venglustat de Sanofi en examen prioritaire par la FDA pour la maladie de Gaucher de type 3

FDA Sanofi Examen Prioritaire Venglustat Maladie De Gaucher
PRESS RELEASE

published on 05/28/2026 at 07:00, 2 months 15 days ago

Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease
Sanofi's venglustat granted priority review by FDA for treating type 3 Gaucher disease. Potential first US therapy for neurological manifestations with target action date on November 25, 2026

FDA Sanofi Venglustat Gaucher Disease Neurological Manifestations
PRESS RELEASE

published on 05/28/2026 at 07:00, 2 months 15 days ago

Communiqué de presse : Le venglustat de Sanofi a été accepté pour un examen prioritaire aux États-Unis afin de traiter la maladie de Gaucher de type 3
Sanofi's venglustat granted priority review by FDA for type 3 Gaucher disease treatment. Potential first US therapy for neurological manifestations. Action date set for Nov 25, 2026

FDA Sanofi Venglustat Type 3 Gaucher Disease Priority Review
BRIEF

published on 05/19/2026 at 18:42, 2 months 23 days ago

Sanofi Reports Voting Rights and Share Information for April 2026

Voting Rights French Commercial Code Shares Sanofi April 2026
BRIEF

published on 05/19/2026 at 18:42, 2 months 23 days ago

Sanofi publie les informations relatives aux droits de vote et aux actions pour avril 2026

Actions Droit De Vote Sanofi Code De Commerce Français Avril 2026
PRESS RELEASE

published on 05/19/2026 at 18:37, 2 months 23 days ago

Sanofi: Information concerning the total number of voting rights and shares - April 2026
Sanofi discloses total voting rights and shares information as per French Commercial Code and French stock market authority regulations

French Commercial Code Total Voting Rights Shares Information Sanofi Stock Market Authority

Accesswire

Published on 08/12/2026 at 00:00, 7 hours 46 minutes ago

Organto Foods Reports Record Second Quarter 2026 Financial Results
Published on 08/11/2026 at 23:40, 8 hours 6 minutes ago

RJK Explorations Ltd. Announces Private Placement for Gross Proceeds of up to $100,000
Published on 08/11/2026 at 23:15, 8 hours 31 minutes ago

Fermi and Hillcore Energy Capital Announce 2.6 Gigawatt Power Strategic Alliance for Project Matador
Published on 08/11/2026 at 23:00, 8 hours 46 minutes ago

Prospectiva Resources Ltd. Completes Qualifying Transaction
Published on 08/11/2026 at 22:55, 8 hours 51 minutes ago

NV Gold Announces Non-Brokered Private Placement

View all ACCESSWIRE

EQS Group

Published on 08/12/2026 at 07:30, 16 minutes ago

BIKE24 continues growth trajectory in the second quarter of 2026 and strengthens its position in the European market
Published on 08/12/2026 at 07:30, 16 minutes ago

wienerberger strengthens its position in infrastructure and renovation – Q2 2026 results
Published on 08/12/2026 at 07:30, 16 minutes ago

Sensirion’s SGM5304 gas meter module successfully achieves EN 17526 certificatio
Published on 08/12/2026 at 07:30, 16 minutes ago

GESCO recorded a solid performance in the first half of 2026 despite persistently challenging conditions
Published on 08/12/2026 at 07:30, 16 minutes ago

Hannover Re generates very good half-year result and remains on track to achieve full-year guidance

Les Echos

Published on 08/11/2026 at 17:45, 14 hours 1 minute ago

DAMARTEX / Droits de vote bruts et réels au 31 juillet 2026
Published on 08/11/2026 at 17:40, 14 hours 6 minutes ago

Infotel : Déclaration des transactions sur actions propres réalisées du 3 au 7 août 2026 dans le cadre du programme de rachat d’actions
Published on 08/10/2026 at 18:00, 1 day 13 hours ago

AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 1 day 13 hours ago

AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
Published on 08/10/2026 at 17:45, 1 day 14 hours ago

Weekly share buyback

View all LES ECHOS COMFI WIRE